Moberg Pharma, Karo Healthcare Add New Markets in Expanded Licensing Deal for Nail Fungus Drug
24 april, 13:17
24 april, 13:17
07:17 AM EDT, 04/24/2026 (MT Newswires) -- Moberg Pharma (MOB.ST) said Friday it added new markets in its exclusive licensing deal with Karo Healthcare for nail fungus treatment MOB-015.
As agreed, Sweden-based Karo Healthcare may also commercialize MOB-015 in Australia, New Zealand, South Korea, and Taiwan, under the brand name Lamisil. The companies'initial collaboration covered 19 European markets.
Financial terms of the deal were not disclosed.
24 april, 13:17
07:17 AM EDT, 04/24/2026 (MT Newswires) -- Moberg Pharma (MOB.ST) said Friday it added new markets in its exclusive licensing deal with Karo Healthcare for nail fungus treatment MOB-015.
As agreed, Sweden-based Karo Healthcare may also commercialize MOB-015 in Australia, New Zealand, South Korea, and Taiwan, under the brand name Lamisil. The companies'initial collaboration covered 19 European markets.
Financial terms of the deal were not disclosed.
Rapporter
Analys
Valet 2026
Rapporter
Analys
Valet 2026
1 DAG %
Senast

OMX Stockholm 30
−0,97%
(vid stängning)
Tomra Systems
Idag, 07:00
Tomra: Kvalitetsbolag i svacka?
Bolåneräntor
Igår, 07:00
Bankerna med lägst bolåneränta
Nordnet
24 april, 17:40
Börsen stängde neråt – ras för Electrolux
Volvo
24 april, 16:15
Analytikern om Volvo: "Marginalen är lite dopad"
OMX Stockholm 30
1 DAG %
Senast
3 101,08